An observational study in Myocardial Infarction (MI) and Dyslipidemias, sponsored by Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga · Observational
Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI).
Eligible patients are informed about the registry by treating physicians or their medical teams and receive an individual access link or QR code. Following electronic informed consent and registration, participants provide clinical and follow-up information through the brite™ platform.
Clinical data, including LDL-C values and lipid-lowering treatment, can be entered by the participants or obtained from uploaded medical documents. The platform enables participants to follow the course of their LDL-C values and provides reminders for scheduled follow-up data collection.
Medical treatment is determined independently by the treating physicians as part of routine clinical care and is not assigned by the registry. The registry aims to assess LDL-C target attainment over time, changes in lipid-lowering treatment, treatment adherence and cardiovascular outcomes following myocardial infarction.
Germany on Target Registry is a prospective patient registry investigating lipid management and cardiovascular secondary prevention following acute myocardial infarction in Germany.
Adults following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) may be informed about the registry by participating physicians and medical institutions. The role of the physicians is primarily limited to identifying potentially eligible patients, providing information about the registry and supplying an individual access link or QR code.
Following registration and electronic informed consent, further study participation is conducted through the Brite™ digital platform provided by XO Life. Participants provide follow-up information directly through the platform. Relevant laboratory values can be entered manually or obtained from medical documents uploaded by the participant.
Baseline information includes characteristics of the index myocardial infarction, LDL-C values at admission and/or discharge, lipid-lowering treatment and relevant cardiovascular risk factors and laboratory parameters. Follow-up assessments document LDL-C values, changes in lipid-lowering therapy and additional clinical information.
The primary focus of the registry is the proportion of participants achieving the predefined LDL-C target of \<55 mg/dL and the maintenance of LDL-C target attainment during follow-up.
Secondary objectives include characterization of the longitudinal LDL-C course, changes and escalation of lipid-lowering therapy, treatment adherence, reported suspected adverse drug reactions and cardiovascular events during follow-up.
The registry does not prescribe a specific lipid-lowering treatment or modification of treatment. Decisions regarding pharmacological treatment remain the responsibility of the participant's treating physicians and are made according to routine clinical care.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →This is the only study on the registry with Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adults aged 18 years or older following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) treated in Germany. Potential participants are identified and informed about the registry by physicians or medical institutions and voluntarily enroll using an individual access link or QR code.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) who voluntarily enroll in the Deutschland auf Ziel registry and are prospectively followed through the brite™ platform.
Other: No study-assigned intervention
Participants receive medical care according to routine clinical practice. The registry does not prescribe or assign lipid-lowering treatment. Lipid-lowering therapies and subsequent treatment changes are documented as part of the observational data collection.
LDL-C target attainment
The primary endpoint of the study/registry is the achievement and maintenance of the LDL-C target level recommended by the current ESC/EAS guidelines for high-risk cardiovascular patients during the follow-up period. Assessment is based on documented LDL-C measurements taken at specified time points (after 6 weeks, 3, 6, and 12 months, as well as during the subsequent long-term follow-up).
Time frame: 12 months
Absolute change in LDL cholesterol
Absolute change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments. Unit: mg/dL
Time frame: Baseline to 60 month
Percentage change in LDL cholesterol
Percentage change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments. Unit: %
Time frame: Baseline to 60 Month
Body weight
Body weight documented for registry participants. Unit: kg
Time frame: Baseline
Body height
Body height documented for registry participants. Unit: cm
Time frame: Baseline
Body mass index
Body mass index calculated from documented body weight and height. Unit: kg/m²
Time frame: Baseline
HDL cholesterol concentration
High-density lipoprotein cholesterol (HDL) cholesterol concentration documented during registry follow-up. Unit: mg/dL
Time frame: Baseline to 60 month
Triglyceride concentration
Triglyceride concentration documented during registry follow-up.
Time frame: Baseline to 60 mionth
Lipoprotein(a) concentration
Lipoprotein(a) concentration documented during registry follow-up. Unit: nmol/L or mg/dL
Time frame: Baseline
HbA1c
Glycated hemoglobin (HbA1c) value documented during registry follow-up. Unit: %
Time frame: Baseline to 60 month
hsCRP
High-sensitivity C-reactive protein (hsCRP) concentration documented during registry follow-up. Unit: mg/L
Time frame: Baseline to 60 month
Blood pressure
Systolic and diastolic blood pressure documented during registry follow-up. Unit: mmHg
Time frame: Baseline
Changes in lipid-lowering therapy during follow-up
Proportion of participants with a documented change in lipid-lowering therapy during follow-up, including initiation, discontinuation, substitution, or modification of lipid-lowering medication.
Time frame: Baseline to 60 month
Proportion of participants with documented intensification of lipid-lowering therapy
Proportion of participants with documented intensification of lipid-lowering therapy during follow-up.
Time frame: Baseline to 60 month
Participant-reported adherence to prescribed lipid-lowering therapy
Participant-reported adherence to prescribed lipid-lowering therapy during registry follow-up.
Time frame: Baseline to 60 month
Occurrence of cardiovascular events during follow-up
Proportion of participants experiencing at least one cardiovascular event during registry follow-up. Cardiovascular events are defined as recurrent ST-elevation myocardial infarction (STEMI), recurrent non-ST-elevation myocardial infarction (NSTEMI), ischemic stroke, or unplanned coronary revascularization.
Time frame: Baseline to 60 month
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2036, 109 months later.
Of 296 non-industry observational studies under Myocardial Infarction, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 140. This study's planned 109 months is above that.
Counting every sponsor, half of 333 studies reached it within 48 months; a quarter within 17 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.